In addition, the potentially escalated metabolic disorder due to the longer-lasting action of ACE2 inhibitor could slow-down or even suppress the onset of compensatory vasoactive mechanisms associated with the activation of the sulfide signaling pathway [61]. This evidence concerns the gene ACE2 and Other metabolic disease.